Melanotan I

Plain-English version: Melanotan I is a small, lab-made peptide that mimics a hormone your body already uses to control skin color. When it binds to the pigment-cell receptor, those cells make more of the brown-black pigment (eumelanin) that tans and protects skin. Its formal drug name is afamelanotide, and it is sold as a prescription implant called Scenesse.

Chemically, Melanotan I is [Nle4-D-Phe7]-α-MSH — a linear analog of the natural hormone α-melanocyte-stimulating hormone (α-MSH), with two amino-acid substitutions that make it far more stable and potent than the natural version. In older research papers you will also see it called NDP-MSH or simply melanotan-I. It was developed by the same University of Arizona melanocortin program that produced its cousins, and it belongs to a well-studied drug family.^[5]

The single most important distinction on this page

Melanotan I and Melanotan II are different molecules, not "version 1" and "version 2" of the same thing. The real differences are structural, how each is delivered, and regulatory status — not, despite a widespread myth, receptor selectivity:

• Melanotan I (afamelanotide) is a linear [Nle4-D-Phe7]-α-MSH analog. Contrary to what is often claimed, it is not MC1R-selective — like natural α-MSH it is a superpotent, non-selective agonist across the melanocortin receptors (MC1R, MC3R, MC4R, and MC5R). What sets it apart in practice is that the approved product is a sustained low-dose implant placed and monitored by a clinician, which keeps systemic effects modest.^[5]
• Melanotan II is a cyclic analog that is also non-selective (MC1R/3R/4R/5R). Sold as a powder and self-injected in bolus doses for tanning, it is much more strongly associated with nausea, spontaneous erections, and appetite suppression. It was never approved anywhere.

So the two share both a tanning mechanism and non-selective pharmacology, but differ sharply in structure, how they are delivered, and — critically — regulatory status.

Approved, but for a narrow purpose

Here is the reality a newcomer must hold onto: afamelanotide is FDA-approved, but only as Scenesse, a 16 mg bioresorbable implant placed under the skin by a trained clinician roughly every two months, and only to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP) — a rare inherited disorder in which sunlight triggers severe burning pain.^[7] The EU approved it in 2014; the US followed in October 2019. It is not approved for cosmetic tanning, general photoprotection, or any other use, and the approved product is never self-injected — it is an implant a doctor inserts. Any injectable powder labeled "Melanotan I" and sold for tanning is an unregulated research chemical, not this medicine. For the broader legal picture, see Are Peptides Legal?

Takeaway first: Your body has a family of "melanocortin" receptors — switches on different cells that do different jobs. The one that drives tanning is MC1R, the skin-pigment switch, and activating it tells your pigment cells to make more protective brown pigment. Melanotan I is a superpotent stimulator of that switch. Like the natural hormone it copies, it also activates the other melanocortin receptors — it is not selective — so what separates it from Melanotan II in practice is how the approved version is delivered, not a cleaner receptor target.

1. MC1R activation drives eumelanin (the tanning mechanism)

Melanocytes — the pigment-producing cells in your skin — carry the MC1R receptor. When α-MSH (or a mimic like Melanotan I) binds MC1R, it switches the cell toward making eumelanin, the brown-black pigment that both darkens skin and absorbs ultraviolet light. Because the drug stimulates the cells directly, some darkening happens even without much sun, though UV exposure deepens and accelerates it. This mechanism is well established in humans for this specific molecule: the landmark Phase 1 trial injected the synthetic melanotropin into volunteers and produced significant, measurable skin darkening.^[2] Evidence level: human Phase 1 trial.

2. Why the side-effect profile differs — dose and delivery, not selectivity

The melanocortin family has four relevant receptors. MC1R sits on pigment cells; MC4R sits in the brain and governs appetite and sexual arousal. A common myth holds that Melanotan I is MC1R-selective while Melanotan II is not — but both peptides are non-selective agonists that also engage MC4R. The difference people actually notice comes from dose and delivery: the approved afamelanotide product releases a low, steady dose from a bioresorbable implant under clinical supervision, whereas Melanotan II is self-injected as a bolus, which drives sharper MC4R-mediated effects. In other words, the milder profile is a property of the approved regimen, not of the molecule's receptor selectivity.^[5] Evidence level: receptor pharmacology and review.

3. Photoprotection — more pigment, less UV damage

Eumelanin is not just cosmetic; it physically absorbs UV and scavenges the free radicals UV creates, which reduces DNA damage in skin. In EPP, the goal is different — it is to raise the skin's tolerance so patients can be in light without the searing pain their disorder causes — but the underlying tool is the same melanocortin pigment response. In a controlled human study combining the peptide with solar UV, treated skin showed roughly 47% fewer UV-induced "sunburn cells," and untreated controls needed about 50% more sun-exposure time to reach an equivalent tan.^[4] Evidence level: small controlled human trial (24 subjects).

What happens in the body (pharmacokinetics)

In humans, subcutaneous Melanotan I is completely absorbed (full bioavailability versus intravenous dosing), clears quickly from the blood (elimination half-life roughly 0.8–1.7 hours), and is barely excreted through the kidneys (under ~3.9%). Oral dosing produced no detectable drug — it is destroyed before it can act, which is why the approved product is an implant and research use is injected, never swallowed. Despite the short blood half-life, the tanning effect is slow and durable: it peaked about one week after a ten-dose regimen and persisted for roughly three weeks afterward, because pigment lives in the skin cells long after the drug is gone.^[3]

How to read this section: Melanotan I is unusual for a research peptide because it actually has human trial data — both for its approved disease use and for tanning. For each area below we give the plain-English claim, the mechanism, the population studied, the observed effect, and the limitation. The strongest, best-graded evidence is for the approved EPP indication; the tanning and photoprotection evidence is real but comes from small, decades-old Phase 1 studies.

Increasing pain-free light exposure in EPP (the approved, best-evidenced benefit)

Claim: lets people with erythropoietic protoporphyria spend more time in light without triggering burning pain. Mechanism: MC1R-driven eumelanin raises the skin's tolerance to light. Population: 168 adults with EPP across two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials (EU n=74, US n=94). Effect: the 16 mg afamelanotide implant every 60 days significantly increased pain-free direct-sunlight exposure and improved quality of life versus placebo, with an acceptable adverse-event profile.^[1] Limitation: EPP is rare, so the trials were modest in size; the benefit is measured as more tolerable light time, not a cure. This is the evidence base FDA and the EMA relied on for approval.^[7]

Skin tanning

Claim: darkens skin with reduced sun exposure. Mechanism: MC1R activation drives eumelanin synthesis. Population: healthy volunteers in early Phase 1 pharmacology trials. Effect: subcutaneous [Nle4-D-Phe7]-α-MSH produced significant, objectively measured skin darkening; in the pharmacokinetic study, tanning of the forehead, arms, and neck peaked at one week and persisted three weeks after a ten-dose regimen.^[2][3] Limitation: these are small, decades-old Phase 1 studies designed to prove the mechanism and characterize the drug, not to support cosmetic tanning. They validate that the melanocortin tanning mechanism works in humans — they do not make unregulated tanning use safe or approved.

Photoprotection

Claim: more baseline pigment means fewer UV-damaged cells. Mechanism: eumelanin absorbs UV and scavenges free radicals. Population: 24 human subjects across three studies combining the peptide with solar UV. Effect: roughly 47% fewer UV-induced sunburn cells at the irradiated site, enhanced and prolonged tanning, and controls needing about 50% more sun-exposure time for an equivalent tan.^[4] Limitation: small sample, surrogate endpoints (sunburn cells, not skin-cancer rates). "Fewer sunburn cells" is a biological signal of reduced UV damage, not proof of cancer prevention — and pigment-driving drugs carry their own pigmented-lesion monitoring concerns (see Side Effects).

The honest bottom line on benefits

• The approved benefit is real and well-evidenced — but it is for a rare disease (EPP), delivered as a clinician-placed implant, not a tanning shortcut.
• The tanning and photoprotection data are genuine but thin: small Phase 1 studies from the 1990s–2000s that prove mechanism, not cosmetic safety.
• None of the human tanning evidence justifies unregulated injectable use. The studies used pharmaceutical-grade material under medical supervision; the powder sold online is neither.
• Note the trap: some sellers cite Melanotan I's respectable trial record to sell an unregulated product that was never the compound tested. The evidence and the product are not the same thing.

Read this first: there are two completely different "doses" of Melanotan I, and conflating them is the central mistake people make. One is the approved medical protocol — a clinician-placed implant with a defined dose. The other is the unregulated tanning practice — self-injected powder with no validated dose at all. We describe both, clearly labeled, for understanding and harm reduction, not as medical guidance to self-administer an unapproved product.

The approved medical protocol (Scenesse, EPP only)

Parameter	Approved regimen
Form	16 mg bioresorbable implant (a small rod placed under the skin)
Route	Subcutaneous, inserted by a trained clinician — never self-injected
Frequency	Every ~60 days (about every 2 months)
Indication	Increasing pain-free light exposure in adults with EPP only

The implant slowly releases afamelanotide over the interval, then dissolves. Because it is placed and monitored by a clinician, dosing, timing, and pigmented-lesion surveillance are all handled in a medical setting. This is the only form of Melanotan I with an established, trial-backed dose.^[1][7]

The unregulated tanning practice (not validated, not endorsed)

The injectable powder sold online has no clinically validated tanning dose, because no cosmetic-tanning trial ever established one. The Phase 1 studies that inform any figures used research-grade material under supervision. The pharmacokinetic study, for example, used a ten-dose subcutaneous regimen after which tanning peaked at one week and lasted about three weeks.^[3] That describes a research schedule — it is not a validated consumer protocol, and the powder's actual content and purity are unknown.

Reconstitution math (for understanding the research chemical)

Research-chemical Melanotan I ships as a lyophilized (freeze-dried) powder that would be mixed with bacteriostatic water. The core formula is the same as any peptide:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 10 ÷ 2 = 5 mg/mL, i.e. 5,000 mcg per mL. To measure a hypothetical 500 mcg amount: 500 ÷ 5,000 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe.

Vial	BAC water	Concentration	500 mcg	1,000 mcg
10 mg	2 mL	5.0 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)
10 mg	1 mL	10.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)
5 mg	1 mL	5.0 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)

The peptide calculator and bacteriostatic water calculator can check these volumes, and the reconstitution guide walks through the mechanics. We include the math for transparency, not to endorse dosing an unapproved compound — there is no validated tanning dose to plug in, and the safety review below explains why the practice carries real risk.

Why oral does not work

Do not expect any effect from swallowing Melanotan I. In the human pharmacokinetic study, oral dosing produced no detectable drug — the peptide is degraded before absorption.^[3] That is precisely why the approved product is an implant and all research use is by injection.

Straight talk: Melanotan I has a better-defined safety picture than most research peptides because of its trial history, and its approved low-dose implant delivery spares it the worst of Melanotan II's systemic effects — not, as is often claimed, receptor selectivity, since afamelanotide is itself a non-selective melanocortin agonist. But "better than Melanotan II" is not "safe for unsupervised tanning." The approved implant is monitored by a clinician; the powder sold online is not, and that is where most of the risk lives.

Side effects seen in the approved (Scenesse) trials

Effect	Frequency	Severity	Notes
Implant-site reaction	Common	Mild	Redness or discomfort where the rod is placed
Headache	Common	Mild	Reported across the melanocortin class
Nausea	Common	Mild	Milder than with self-injected Melanotan II
Fatigue	Common	Mild	Transient

Overall, the Phase 3 EPP trials reported an acceptable adverse-event profile — the reason the drug cleared regulatory review.^[1] Because the approved product delivers a low, steady dose from an implant rather than a self-injected bolus, the pronounced nausea, spontaneous erections, and appetite suppression associated with Melanotan II are not hallmark features of the Scenesse regimen — even though afamelanotide, like Melanotan II, is a non-selective melanocortin agonist.^[5]

Risks specific to unregulated (non-Scenesse) tanning use

A peer-reviewed review of unregulated α-MSH analogue use documents a very different risk landscape for the research-chemical route:

• Dosing and preparation uncertainty: unknown purity and content mean users cannot know what they are actually injecting.^[6]
• Sympathomimetic (stimulant-like) reactions: racing heart, blood-pressure swings, and nausea have been reported with unregulated melanotropin use.^[6]
• Melanocyte proliferation and pigmented-lesion change: because these drugs drive pigment cells, there is concern about new or changing moles — a signal that overlaps with how melanoma is detected.^[6]

The pigmented-lesion / melanoma monitoring concern

This is the most important long-term consideration for any melanogenic drug. Because Melanotan I stimulates pigment cells, existing moles can darken and new pigmented spots can appear. Two problems follow: darkening can mask the early warning signs of melanoma, and the drug's melanogenic action itself keeps long-term melanoma and pigmented-lesion surveillance on the table as a monitoring consideration — which is exactly why the approved product is used with clinical oversight.^[7] Anyone with a personal or family history of melanoma, or many atypical moles, should treat this as a hard stop for unsupervised use.

Who should avoid it

• Anyone considering it for cosmetic tanning — the approved product is not for that, and the unregulated alternative carries the risks above.
• People with a history of melanoma or numerous atypical moles — the pigmented-lesion concern is most acute here.
• Pregnant or breastfeeding individuals — no adequate safety data.
• Anyone with cardiovascular conditions — given the reported sympathomimetic reactions with unregulated use.

For broader context, see Are Peptides Safe? and Peptide Side Effects. If you have EPP, this is a conversation for your dermatologist, not a research vial.

Why this section matters: "Melanotan I" splits into two supply worlds that share a name and nothing else. One is a regulated prescription implant; the other is an unregulated powder. Knowing which you are dealing with is the whole game.

The regulated product (Scenesse / afamelanotide)

• Prescription-only, placed by a certified clinician; not sold direct to consumers.
• Manufactured to pharmaceutical standards with defined dose, purity, and sterility.
• Available only for the approved EPP indication through specialty channels.

If a website offers to sell you "Scenesse" or "afamelanotide implants" without a prescription and a clinic, that is a red flag by itself — the legitimate product does not reach patients that way.^[7]

The unregulated research chemical

Injectable "Melanotan I" powder sold online is a research chemical with no quality oversight. If you are evaluating such a product despite the risks, the same COA literacy that applies to any peptide is the minimum bar:

• Third-party COA: independent HPLC purity testing (look for ≥98%) and mass-spectrometry identity confirmation.
• Batch-specific results: the COA should reference the exact lot, not a generic sample.
• Endotoxin (LAL) testing: essential for anything intended to be injected.
• Lyophilized powder in a sealed, light-protected vial — never a pre-mixed "ready to use" liquid.

Red flags: no COA (or a seller-issued one), pre-mixed liquid, prices far below market, and explicit cosmetic-tanning or medical claims — which signal a non-compliant vendor.

Legal and regulatory status (2026)

• Approved as Scenesse (afamelanotide): FDA October 2019 (EMA 2014), solely for pain-free light exposure in adults with EPP.^[7]
• Not approved for tanning, photoprotection, or any other use. Selling injectable "Melanotan I" for cosmetic tanning is outside any approval and unregulated.
• Not the same as Melanotan II, which is unapproved everywhere — do not let the shared name blur the distinction.

Storage

The approved implant is handled entirely by the clinic. For research-chemical powder, keep unopened lyophilized vials cold and dark (freezer or refrigerator); once reconstituted, refrigerate at 2–8°C, use within a few weeks, never freeze the solution, and discard anything cloudy or discolored. See the full peptide storage guide, and for the complete legal picture read Are Peptides Legal?

The two tanning peptides are constantly confused, but they differ in the ways that matter most: structure, how each is delivered, side effects, and legal status. (Receptor selectivity is not one of them — both are non-selective melanocortin agonists.) None of this is a head-to-head trial — it contrasts the two molecules' pharmacology and regulatory records.

Factor	Melanotan I (afamelanotide)	Melanotan II
Structure	Linear [Nle4-D-Phe7]-α-MSH	Cyclic (ring-shaped) analog
Receptor target	Non-selective (MC1R/3R/4R/5R)	Non-selective (MC1R/3R/4R/5R)
Systemic side effects	Milder in practice (sustained low-dose implant)	Nausea, erections, appetite loss (bolus dosing)
Regulatory status	FDA-approved (Scenesse) for EPP	Not approved anywhere
Human trials	Phase 3 (EPP) + Phase 1 (tanning/PK)	No completed efficacy trials

The through-line: Melanotan I is the better-evidenced and — in its approved implant form — legitimately regulated molecule, while Melanotan II is the unapproved one with a case-report harm record. For a full breakdown, read Melanotan I vs Melanotan II.